Progenitor Cell Mobilization Observed in Subjects with Critical Limb
Ischemia Treated with ZFP Therapeutic
MIAMI, May 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of data from a Phase 1 clinical trial of a zinc finger DNA-binding protein activator of vascular endothelial growth factor (ZFP-VEGF) in subjects with critical limb ischemia (CLI). The data demonstrate that administration of ZFP-VEGF resulted in a statistically significant increase in circulating progenitor or stem cells in the peripheral blood. In addition, within a subgroup in which bone marrow cells were examined before and after treatment, the data suggests that subjects who showed the most marked clinical improvements, as judged by limb salvage, ulcer healing, reduction in pain and increased oxygen concentrations in the tissues, also showed the greatest increase in bone marrow stem cells. The trial was conducted by principal investigator Brian Annex, M.D., Director, Vascular Medicine and his colleagues at Duke University Medical Center.
"The data obtained in this clinical trial are very interesting and may
have important implications for assessing biological activity and efficacy
of this therapeutic strategy," commented the presenter, Robert Mitchell,
M.D., of the department of medicine at Duke University Medical Center.
"Several of the subjects in this trial were already scheduled for
amputation but chose to enroll in this important trial. Within a subgroup
analysis, the data demonstrate that the best clinical responders had the
largest fold increase in bone marrow stem cells twelve days after dosing.
Increased mobilization of stem cells, which may be involved in tissue
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved